scispace - formally typeset
W

Wolfgang Lilleby

Researcher at Oslo University Hospital

Publications -  86
Citations -  1615

Wolfgang Lilleby is an academic researcher from Oslo University Hospital. The author has contributed to research in topics: Prostate cancer & Radiation therapy. The author has an hindex of 20, co-authored 74 publications receiving 1338 citations. Previous affiliations of Wolfgang Lilleby include Rikshospitalet–Radiumhospitalet & University of Oslo.

Papers
More filters
Journal ArticleDOI

Radical Prostatectomy, External Beam Radiotherapy, or External Beam Radiotherapy With Brachytherapy Boost and Disease Progression and Mortality in Patients With Gleason Score 9-10 Prostate Cancer.

TL;DR: Among patients with Gleason score 9-10 prostate cancer, treatment with EBRT+BT with androgen deprivation therapy was associated with significantly better prostate cancer–specific mortality and longer time to distant metastasis.
Journal ArticleDOI

Long-term morbidity and quality of life in patients with localized prostate cancer undergoing definitive radiotherapy or radical prostatectomy

TL;DR: In spite of considerable malignancy and/or treatment-related morbidity QoL was good or only slightly impaired in the majority of patients with localized prostate cancer who presented with stable disease > 1 year after definitive radiotherapy or radical prostatectomy with no difference as compared to the age-matched normal population.
Journal ArticleDOI

Phase I/IIa clinical trial of a novel hTERT peptide vaccine in men with metastatic hormone-naive prostate cancer.

TL;DR: Treatment with UV1 and GM-CSF gave few adverse events and induced specific immune responses in a large proportion of patients unselected for HLA type, warranting further clinical studies in mPC.
Journal ArticleDOI

Tomato-based randomized controlled trial in prostate cancer patients: Effect on PSA

TL;DR: Three week nutritional interventions with tomato-products alone or in combination with selenium and n-3 fatty acids lower PSA in patients with non-metastatic prostate cancer, suggesting that the effect may depend on both aggressiveness of the disease and the blood levels of lycopene, selenIUM and omega- 3 fatty acids.